Neumora Therapeutics reported net income of -$43.08M for the quarter ended Jun 2026. This income statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 32.59M | 32.61M | 32.71M | 32.82M | 46.69M | 65.02M | 159.52M | 160.03M | 161.56M | 161.71M | 161.75M | 161.95M | 167.09M | 174.26M | 185.28M | 187.90M |
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 22.55M | 23.52M | 29.48M | 32.77M | 41.60M | 38.86M | 45.76M | 48.63M | 60.63M | 45.91M | 52.15M | 38.72M | 40.52M | 44.67M | 38.60M | 29.28M |
| Selling, General & AdministrativeSG&A | 8.05M | 7.20M | 9.68M | 9.29M | 15.26M | 11.24M | 14.32M | 15.19M | 16.02M | 17.01M | 18.79M | 15.32M | 12.18M | 13.81M | 14.27M | 12.91M |
| Other Operating ExpensesOther Opex | 63.90M | 5.00M | ||||||||||||||
| Operating ExpensesOpex | 30.60M | 30.72M | 39.17M | 42.06M | 56.86M | 114.00M | 60.07M | 63.82M | 76.65M | 62.92M | 70.94M | 54.04M | 57.70M | 58.48M | 52.86M | 42.19M |
| Operating IncomeOp. Inc | -30.60M | -30.72M | -39.17M | -42.06M | -56.86M | -114.00M | -60.07M | -63.82M | -76.65M | -62.92M | -70.94M | -54.04M | -57.70M | -58.48M | -52.86M | -42.19M |
| EBIT | -30.60M | -30.72M | -39.17M | -42.06M | -56.86M | -114.00M | -60.07M | -63.82M | -76.65M | -62.92M | -70.94M | -54.04M | -57.70M | -58.48M | -52.86M | -42.19M |
| Non-operating items | ||||||||||||||||
| Non Operating Interest Expenses | 0.44M | 0.75M | 2.04M | 1.85M | 1.82M | |||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.41M | 2.29M | 0.48M | -0.15M | 3.84M | 5.65M | -0.07M | -0.04M | 4.21M | 4.09M | -0.07M | 2.25M | 1.69M | 1.33M | 1.23M | 0.94M |
| Other Non Operating IncomeOther Non Op Inc. | -0.15M | 0.29M | -0.03M | -0.04M | -0.00M | -0.10M | -0.01M | -0.02M | -0.06M | 0.01M | -0.03M | -0.48M | 0.01M | 6.92M | 0.06M | -0.01M |
| Non Operating IncomeNon Op. Inc. | 1.26M | 2.57M | 3.54M | 3.52M | 3.84M | 5.54M | 6.35M | 5.25M | 4.15M | 4.10M | 3.05M | 1.33M | 0.94M | -0.97M | -0.56M | -0.89M |
| Net income details | ||||||||||||||||
| EBT | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.58M | -72.49M | -58.82M | -67.89M | -52.71M | -56.76M | -59.45M | -53.43M | -43.08M |
| Tax ProvisionsTaxes | 0.12M | 0.05M | 0.10M | 0.03M | -49.86M | 0.03M | ||||||||||
| Profit After TaxPAT | -29.63M | -27.77M | -35.62M | -38.54M | -53.03M | -108.73M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.74M | -56.76M | -59.46M | -53.46M | -43.08M |
| Income from Continuing OperationsIncome (Continuing) | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.73M | -56.76M | -9.60M | -53.46M | -43.08M |
| Consolidated Net IncomeConsol Net Inc. | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.73M | -56.76M | -9.60M | -53.46M | -43.08M |
| Income towards Parent CompanyParent Net Inc | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.73M | -56.76M | -9.60M | -53.46M | -43.08M |
| Net Income towards Common StockholdersNet Income | -29.20M | -28.43M | -38.69M | -38.54M | -53.03M | -108.46M | -53.72M | -58.70M | -72.55M | -58.82M | -67.99M | -52.73M | -56.76M | -9.60M | -53.46M | -43.08M |
| Additional items | ||||||||||||||||
| EPS (Basic) | -1.06 | -1.05 | -1.32 | -1.28 | -1.14 | -1.67 | -0.34 | -0.37 | -0.45 | -0.37 | -0.42 | -0.33 | -0.35 | -0.06 | -0.30 | -0.23 |
| EPS (Diluted) | -1.06 | -1.05 | -1.32 | -1.28 | -1.14 | -1.67 | -0.34 | -0.37 | -0.45 | -0.37 | -0.42 | -0.33 | -0.35 | -0.06 | -0.30 | -0.23 |
| Shares Outstanding | 27.65M | 27.21M | 29.28M | 30.12M | 46.69M | 65.02M | 157.94M | 158.98M | 159.58M | 159.38M | 161.45M | 161.69M | 161.84M | 163.39M | 179.87M | 185.16M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 27.65M | 27.21M | 29.28M | 30.12M | 46.69M | 65.02M | 157.94M | 158.98M | 159.58M | 159.38M | 161.45M | 161.69M | 161.84M | 163.39M | 179.87M | 185.16M |
| EBITDA | -30.60M | -30.72M | -39.17M | -42.06M | -56.86M | -114.00M | -60.07M | -63.82M | -76.65M | -62.92M | -70.94M | -54.04M | -57.70M | -58.48M | -52.86M | -42.19M |
| Interest ExpensesInt Expense | 0.44M | 0.75M | 2.04M | 1.85M | 1.82M | |||||||||||
| Tax Rate | -0.21 | -0.07 | -0.15 | -0.05 | 83.86 | -0.06 |